Shares of Vivus (VVUS -9.1%) trail off after an updated analysis of the likely votes of FDA...

|By:, SA News Editor

Shares of Vivus (VVUS -9.1%) trail off after an updated analysis of the likely votes of FDA panel members tips toward a rejection for the firm's obesity drug Qnexa on Feb. 22.